[Current status and future prospects of C-type natriuretic peptide].
Park
Kwijun
K
Department of Medicine and Clinical Science, Kyoto University Graduate School of Medicine.
Itoh
Hiroshi
H
Nakao
Kazuwa
K
D000130:Achondroplasia / Q000188:drug therapy / Q000209:etiology; D000818:Animals; D001161:Arteriosclerosis / Q000188:drug therapy / Q000209:etiology; D002455:Cell Division / Q000235:genetics; D020219:Chondrogenesis / Q000235:genetics; D006152:Cyclic GMP / Q000502:physiology; D017869:Cyclic GMP-Dependent Protein Kinases / Q000502:physiology; D004730:Endothelium, Vascular / Q000166:cytology / Q000502:physiology; D006162:Guanylate Cyclase / Q000502:physiology; D006801:Humans; D020098:Natriuretic Peptide, C-Type / Q000494:pharmacology / Q000502:physiology / Q000627:therapeutic use; D017461:Receptors, Atrial Natriuretic Factor / Q000502:physiology; D012038:Regeneration / Q000235:genetics; D014661:Vasoconstriction / Q000235:genetics; D000099242:Atrial Natriuretic Factor Receptor B
D006152:Cyclic GMP; D017869:Cyclic GMP-Dependent Protein Kinases; D006162:Guanylate Cyclase; D020098:Natriuretic Peptide, C-Type; D017461:Receptors, Atrial Natriuretic Factor; D000099242:Atrial Natriuretic Factor Receptor B